Leadership & Pay ·
Valion Bio appoints Dean Zikria as Interim CEO after Sheryle Bolton resigns from the Board
TIVCValion Bio, Inc.
Valion Bio, Inc. appointed Dean Zikria as Interim Chief Executive Officer effective September 22, 2026, while Sheryle Bolton resigned from the Board immediately on September 17, 2026. Thomas Jensen was named Chair of the Board and Compensation Committee, and Jared Malbin became Chair of the Audit and Risk Committee. Zikria’s compensation includes a monthly fee of $23,333, 50,000 restricted stock units, and potential bonuses upon closing a strategic transaction. Lisa Wolf continues as President, COO, and CFO. Valion Bio is a clinical-stage biopharmaceutical company developing biologics for cytoprotection and immune modulation.